Approved by EMA, novel oral AKT inhibitor in combination improves clinical outcomes and prolongs quality of life in patients with advanced HR+/HER2- breast cancer

by VHIO

The European Medicines Agency (EMA) recently approved the combination of novel AKT inhibitor capivasertib with fulvestrant for patients with hormone receptor (HR)-positive, HER2-negative advanced or m...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Ona Therapeutics Raises $86.6 Million Se...

by Ysios Capital

Proceeds to support clinical development of lead first-in-class progra...

Photos Stream